Objective: To evaluate the effects of a multidisciplinary weight management intervention, so as to provide a reference for the formulation of overweight and obesity intervention measures. Methods: From April to September 2025, overweight and obese residents aged 18-60 years who participated in a weight loss competition at the Health Management Center of Beilun People's Hospital in Ningbo City were selected as study subjects. They were divided into a control group and an intervention group. The control group received conventional weight management, while the intervention group received the multidisciplinary integrated weight management in addition to the conventional weight management, for a total intervention period of 8 weeks. Weight, body mass index (BMI), waist circumference, hip circumference, waist-to-hip ratio, fasting blood glucose (FBG), triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and blood pressure were collected before and after the intervention through physical examinations and laboratory tests. The generalized estimating equations (GEE) method was employed to analyze the differences in indicators between the two groups before and after the intervention. Results: The control group comprised 241 participants, including 161 females (66.80%), with a mean age of (35.66±7.80) years. The intervention group consisted of 127 participants, including 86 females (67.72%), with a mean age of (36.80±7.05) years. No statistically significant differences were observed between the two groups at baseline in terms of age, gender, weight, BMI, or waist-to-hip ratio (all P>0.05). Results from the GEE analysis indicated significant interactions between group and time for weight, BMI, waist circumference, and hip circumference (all P<0.05) with greater reductions in these parameters observed in the intervention group compared to the control group before and after the intervention. Similarly, significant interactions between group and time were observed for FBG, TG, TC, and LDL-C (all P<0.05), with the intervention group demonstrating larger decreases in these markers compared to the control group. However, no statistically significant interactions between group and time were observed for waist-to-hip ratio, HDL-C, systolic blood pressure, and diastolic blood pressure (all P>0.05). Following the intervention, a weight loss exceeding 10% was achieved by 13 participants (5.39%) in the control group and 62 participants (48.82%) in the intervention group. The proportion of individuals with a weight loss exceeding 10% was significantly higher in the intervention group compared to the control group (P<0.05). Conclusion Compared to conventional weight management, multidisciplinary integrated weight management demonstrated greater efficacy in improving weight-related indicators and blood glucose, blood lipids, and enhancing weight loss outcomes among overweight and obese residents.

Acute respiratory distress syndrome (ARDS) is the leading cause of respiratory failure with high morbidity and mortality. Pulmonary surfactant (PS)-based complementary therapies have exhibited potential for ARDS healing and applied as an adjunctive therapy strategy. Coacervate (Coac) has the characteristics of softness, deformability and excellent molecular enrichment properties, and has attracted extensive attention in the biomedical field. Here PS and coacervate were combined for the potential ARDS treatment. The Coac, fabricated from polyallylamine hydrochloride (PAH) and adenosine triphosphate (ATP) by simple mixing, exhibited soft droplet property and high enrichment for dexamethasone sodium phosphate (DSP). To avoid the fusion effect of membraneless coacervate and endow it with biological functions of PS, liposomes with PS-biomimetic lipid components (PS-lipo) were further introduced to construct PS-biomimetic membranized coacervate (DSP@PS-Coac). The DSP@PS-Coac demonstrated high lung targeting effect and significant penetration efficiency after intravenous injection. Furthermore, PS-lipo replenished the endogenous PS pool and facilitated the distribution of DSP in inflammatory cells in the lung. In the ARDS mouse model, PS-Coac and DSP exerted synergetic anti-inflammatory functions, via reducing the recruitment of inflammatory neutrophils and modulating macrophages into anti-inflammatory phenotype. The overall results confirmed that DSP@PS-Coac may provide a promising delivery option for the treatment of ARDS.

OBJECTIVES: To evaluate the inhibitory effect of Macrothele raveni crude venom against proliferation of different cancer cells and identify the active components in the venom. METHODS: Different cancer cell lines were treated with different concentrations of Macrothele raveni venom for 48 h, and cell proliferation and the half-maximal inhibitory concentrations (IC₅₀) of the venom were assessed with CCK-8 assay. The apoptosis rate of breast cancer MCF7 cells following the treatment was analyzed with flow cytometry, and the changes in cellular caspase-8 and caspase-9 expressions were detected. The crude venom was separated into protein, peptide, and small-molecule compound fractions using gel filtration chromatography and high-performance liquid chromatography (HPLC). The protein and peptide components were identified using proteomics analysis, and small-molecule compounds were structurally characterized using nuclear magnetic resonance (NMR), mass spectrometry (MS), and HPLC. RESULTS The crude venom exhibited strong concentration-dependent inhibitory effects on proliferation of MCF7 cells and nasopharyngeal carcinoma SUNE1 and HONE1 cells (IC₅₀ of 2.14±0.29, 1.57±0.14, and 2.85±0.15 µg/mL, respectively), with less potent inhibitory effects in gastric cancer HGC27 cells and colorectal cancer SW620 cells (IC₅₀ of 3.02±0.27 and 3.02±0.28 µg/mL, respectively). The crude venom significantly promoted MCF7 cell apoptosis likely via the caspase 8 signaling pathway. The protein fraction from the crude venom showed a weak inhibitory effect in MCF7 cells, whereas the peptide fraction exhibited a much stronger inhibitory effect (IC₅₀ of 6.41±0.31 µg/mL). The peptides in the peptide fraction, with relative molecular mass around 10 000, were homologous to those found in Macrothele gigas venom. The small-molecule fraction consisted mainly of nucleotide metabolites without obvious inhibitory effects in MCF7 cells, but its combination with the peptide fraction showed significantly enhanced inhibitory activity. Conclusion The inhibitory effects of Macrothele raveni venom, which vary significantly across different cancer cell lines, are attributed primarily to its peptide components, which may act synergistically with the nucleotide metabolites.
Humans ; Cell Proliferation/drug effects* ; Apoptosis/drug effects* ; Animals ; Cell Line, Tumor ; MCF-7 Cells ; Caspase 8/metabolism* ; Peptides/pharmacology* ; Caspase 9/metabolism*

Objective:To investigate the correlation between vitamin D levels and thyroid hormone sensitivity in euthyroid individuals.Methods:This cross-sectional study included 5 894 euthyroid individuals who underwent health examinations at the Department of Health Management, Peking Union Medical College Hospital, from December 2023 to February 2024. Thyroid feedback quantile-based index (TFQI), TSH index (TSHI), thyrotroph thyroxine resistance index (TT4RI), and the ratio of free triiodothyronine (FT3)/free thyroxine (FT4) were calculated to assess thyroid hormone sensitivity. Participants were categorized into vitamin D deficiency and non-deficiency groups based on serum 25(OH)D levels. The differences in thyroid hormone sensitivity indices and other clinical characteristics between the two groups were compared. Multivariate logistic regression models were used to analyze the association between vitamin D levels and thyroid hormone sensitivity, and stratified analysis was conducted to explore the association in different genders.Results:Among the study participants, 4 731 (80.3%) had vitamin D deficiency. Compared with the non-deficient group, the deficient group had a lower TFQI (-0.03(-0.31, 0.23) and -0.01(-0.28, 0.27)) ( Z=-2.130, P=0.033) and a higher FT3/FT4 ratio ((0.36±0.04) and (0.35±0.04)) ( t=-4.592, P<0.001). After adjusting for confounding factors including gender and age, the risk of impaired central and peripheral thyroid hormone sensitivity significantly increased in the non-deficient group (TFQI ( OR=1.16, 95% CI: 1.01-1.34); FT3/FT4 ( OR=1.23, 95% CI: 1.05-1.45)) (all, P<0.05). Conclusion:In euthyroid individuals, people with higher vitamin D levels have a higher risk of impaired thyroid hormone sensitivity.

Objective:To investigate the correlation between vitamin D levels and thyroid hormone sensitivity in euthyroid individuals.Methods:This cross-sectional study included 5 894 euthyroid individuals who underwent health examinations at the Department of Health Management, Peking Union Medical College Hospital, from December 2023 to February 2024. Thyroid feedback quantile-based index (TFQI), TSH index (TSHI), thyrotroph thyroxine resistance index (TT4RI), and the ratio of free triiodothyronine (FT3)/free thyroxine (FT4) were calculated to assess thyroid hormone sensitivity. Participants were categorized into vitamin D deficiency and non-deficiency groups based on serum 25(OH)D levels. The differences in thyroid hormone sensitivity indices and other clinical characteristics between the two groups were compared. Multivariate logistic regression models were used to analyze the association between vitamin D levels and thyroid hormone sensitivity, and stratified analysis was conducted to explore the association in different genders.Results:Among the study participants, 4 731 (80.3%) had vitamin D deficiency. Compared with the non-deficient group, the deficient group had a lower TFQI (-0.03(-0.31, 0.23) and -0.01(-0.28, 0.27)) ( Z=-2.130, P=0.033) and a higher FT3/FT4 ratio ((0.36±0.04) and (0.35±0.04)) ( t=-4.592, P<0.001). After adjusting for confounding factors including gender and age, the risk of impaired central and peripheral thyroid hormone sensitivity significantly increased in the non-deficient group (TFQI ( OR=1.16, 95% CI: 1.01-1.34); FT3/FT4 ( OR=1.23, 95% CI: 1.05-1.45)) (all, P<0.05). Conclusion:In euthyroid individuals, people with higher vitamin D levels have a higher risk of impaired thyroid hormone sensitivity.

In this research， a comprehensive examination of historical materia medica， medical literature， medical books and contemporary literature was conducted to systematically compile and verify the naming， origin， geographical variations， quality， medicinal properties and processing of Tremolitum， and combined with the physical analysis of 15 batches of samples， with a view to providing a basis for the quality evaluation. The evidences unequivocally support Yangqishi as the rectification of name， while alternative aliases include Baishi， Shisheng， Yangjushi and Yangshi. The primary source of Tremolitum has been the silicate hornblende mineral tremolite throughout recorded history， and its accompanied minerals are mainly chlorite， talc schist， anthophyllite asbestos， etc. In ancient times， the main production area of Tremolitum was situated in the "Yaoshan Mountain" region of Jinan， Shandong province. Presently， it is primarily produced in Hubei， Henan， Shanxi， Hebei and Shandong provinces. The ancient quality evaluation of Tremolitum includes "white color"， "wolf teeth"， "cloud head and rain foot"， "heron hair"， etc. While， modern materia medica mostly evaluates its quality in terms of color， luster and texture， including the characteristics of needle bundle， grayish-white， glossy and easy to be twisted and crushed. Tremolitum is slightly warm， non-toxic， and possesses a salty taste. It is associated with the kidney meridian， known for its benefits in nourishing the fire of the gate of life， warming the kidneys and strengthening the Yang. Common processing methods include fire calcination， elutriation， and processing with wine. Additionally， there is an exclusive processing method known as the "ascending Tremolitum method". Through the X-ray diffraction（XRD） analysis， the commercially available Tremolitum is mainly composed of tremolite［Ca₂Mg₅（Si₄O₁₁）₂（OH）₂］， and the accompanied minerals are calcite and quartz， etc. Its color includes white， light gray， light green and so on， and it is weight and soft texture， irregular cross-section， with obvious fibrous texture and mostly glassy luster. Among the commercially available Tremolitum， samples with high content of tremolite are characterized by high quality features， such as "white color"， "heron hair" and "ease of tearing". Also， Tremolitum is the Fe-bearing heterogeneous species of tremolite， and the two are often symbiotic. Therefore， by the herbal textual research and the comparison of the properties and composition of Tremolitum and its similar species， it has been verified that the primary source of Tremolitum is the silicate hornblende minerals tremolite and actinolite.

Objective This study aimed to identify PAX9 variants in non-syndromic tooth agenesis families of Chi-na,as well as to analyze the genotype-phenotype of non-syndromic tooth agenesis caused by PAX9 variants,which can provide a basis for the genetic diagnosis of tooth agenesis.Methods We collected the data of 44 patients with non-syn-dromic oligodontia who underwent treatment at Stomatological Hospital of Hebei Medical University between 2018 and 2023.Whole-exome sequencing was performed on the peripheral blood of the proband and its core family members,and the variants were verified by Sanger sequencing.Pathogenicity analysis and function prediction of the variants were per-formed using bioinformatics tools.The correlation between the genotype of PAX9 variant and its corresponding pheno-type was examined by reviewing 55 publications retrieved from PubMed.The studies involved 232 tooth agenesis pa-tients with PAX9 variants.Results A novel PAX9 c.447delG(p.Pro150Argfs*62)and a reported PAX9 c.406C>T(p.Gln136*)were identified in two Chinese families.Through bioinformatics analysis and three-dimensional structural mod-eling,we postulated that the frameshift variant was pathogenic.The outcome was the premature cessation of PAX9 pro-tein,which caused severe structural and functional deficiencies.Summarizing the PAX9 genotype-phenotype relationship revealed that patients carrying the PAX9 variant commonly led to loss of the second molars.Conclusion We identified the novel PAX9 c.447delG(p.Pro150Argfs*62)in a Chinese family of non-syndromic oligodontia,expanding the known variant spectrum of PAX9.The most susceptible tooth position for PAX9 variants of tooth agenesis was the second mo-lars and the deciduous molars during the deciduous dentition.

Objective:To investigate whether there are differences in clinical outcomes and perinatal outcomes associated with different initial dosages of gonadotropin (Gn) in expected poor prognosis young patients, diagnosed according to the POSEIDON criteria, undergoing the early-follicular phase long-acting gonadotropin-releasing hormone agonist (GnRH-a) long protocol.Methods:This retrospective cohort study analyzed clinical data from patients who underwent their first in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI)-fresh embryo transfer (ET) cycle at the Reproductive Medicine Center of the First Affiliated Hospital of Zhengzhou University between January 1, 2016, and June 30, 2022. Patients included in the study were those who underwent ovarian stimulation with the early-follicular phase long-acting GnRH-a long protocol and young expected poor prognosis. Patients were divided into three groups based on the starting Gn dosage: low-dose group (Gn<225 U), medium-dose group (225 U≤Gn<300 U), and high-dose group (Gn=300 U). Clinical and perinatal outcomes were compared among the three groups. Results:A total of 1 659 cycles were included in the study, with 316 cycles in the low-dose group, 536 cycles in the medium-dose group, and 807 cycles in the high-dose group. The number of oocytes retrieved in the high-dose group [6.00 (4.00,9.00)] was less than that in the medium-dose group [8.00 (6.00,11.00)] and the low-dose group [11.00 (7.00,13.00)], which in the medium-dose group was less than that in the low-dose group, and the differences were statistically significant (all P<0.017). There were no significant statistical differences in oocyte maturation rate, normal fertilization rate of IVF/ICSI, or high-quality embryo rate among the three groups (all P>0.05). The blastocyst formation rates decreased sequentially in the low-dose group [20.33% (425/2 090)], medium-dose group [17.28% (510/2 951)], and high-dose group [14.62% (518/3 542)], with significant differences between each pair of groups (all P<0.017). There were no significant differences in clinical pregnancy rate, biochemical pregnancy rate, ectopic pregnancy rate, miscarriage rate, chromosomal abnormalities in miscarriage tissues, or preterm birth rate among the three groups (all P>0.05). However, the live birth rate was significantly lower in the high-dose group [47.83% (386/807)] than in the low-dose group [57.28% (181/316), P=0.004]. After adjusting for confounding factors using multivariate logistic regression, the high starting Gn dosage was found to be an independent risk factor for decreased live birth rate (a OR=0.659, 95% CI: 0.462-0.941, P=0.022). There were no significant differences in perinatal outcomes among the groups, regardless of whether confounding factors were adjusted for (all P>0.05). Conclusion:In young patients with expected poor prognosis undergoing their first ovarian stimulation with the long-acting follicular phase protocol, increasing the starting Gn dosage does not increase the number of oocytes retrieved and is associated with a lower blastocyst formation rate and a reduced live birth rate, but does not increase the risk of adverse perinatal outcomes.

Objective:To investigate whether there are differences in clinical outcomes and perinatal outcomes associated with different initial dosages of gonadotropin (Gn) in expected poor prognosis young patients, diagnosed according to the POSEIDON criteria, undergoing the early-follicular phase long-acting gonadotropin-releasing hormone agonist (GnRH-a) long protocol.Methods:This retrospective cohort study analyzed clinical data from patients who underwent their first in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI)-fresh embryo transfer (ET) cycle at the Reproductive Medicine Center of the First Affiliated Hospital of Zhengzhou University between January 1, 2016, and June 30, 2022. Patients included in the study were those who underwent ovarian stimulation with the early-follicular phase long-acting GnRH-a long protocol and young expected poor prognosis. Patients were divided into three groups based on the starting Gn dosage: low-dose group (Gn<225 U), medium-dose group (225 U≤Gn<300 U), and high-dose group (Gn=300 U). Clinical and perinatal outcomes were compared among the three groups. Results:A total of 1 659 cycles were included in the study, with 316 cycles in the low-dose group, 536 cycles in the medium-dose group, and 807 cycles in the high-dose group. The number of oocytes retrieved in the high-dose group [6.00 (4.00,9.00)] was less than that in the medium-dose group [8.00 (6.00,11.00)] and the low-dose group [11.00 (7.00,13.00)], which in the medium-dose group was less than that in the low-dose group, and the differences were statistically significant (all P<0.017). There were no significant statistical differences in oocyte maturation rate, normal fertilization rate of IVF/ICSI, or high-quality embryo rate among the three groups (all P>0.05). The blastocyst formation rates decreased sequentially in the low-dose group [20.33% (425/2 090)], medium-dose group [17.28% (510/2 951)], and high-dose group [14.62% (518/3 542)], with significant differences between each pair of groups (all P<0.017). There were no significant differences in clinical pregnancy rate, biochemical pregnancy rate, ectopic pregnancy rate, miscarriage rate, chromosomal abnormalities in miscarriage tissues, or preterm birth rate among the three groups (all P>0.05). However, the live birth rate was significantly lower in the high-dose group [47.83% (386/807)] than in the low-dose group [57.28% (181/316), P=0.004]. After adjusting for confounding factors using multivariate logistic regression, the high starting Gn dosage was found to be an independent risk factor for decreased live birth rate (a OR=0.659, 95% CI: 0.462-0.941, P=0.022). There were no significant differences in perinatal outcomes among the groups, regardless of whether confounding factors were adjusted for (all P>0.05). Conclusion:In young patients with expected poor prognosis undergoing their first ovarian stimulation with the long-acting follicular phase protocol, increasing the starting Gn dosage does not increase the number of oocytes retrieved and is associated with a lower blastocyst formation rate and a reduced live birth rate, but does not increase the risk of adverse perinatal outcomes.